- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nicotinamide and pyruvate combo improves vision in patients with open-angle glaucoma: JAMA
USA: A combination of nicotinamide and pyruvate improved visual function significantly in the short term, reveals a recent study published in the journal JAMA Ophthalmology. This supports previous experimental research suggesting a role for these agents in glaucoma neuroprotection and confirming the need for long-term studies to establish their usefulness in slowing progression.
Despite a large reduction in intraocular pressure (IOP), open-angle glaucoma may develop. Enhancing mitochondrial efficiency and energy generation may improve retinal ganglion cell survival in animal models of glaucoma, according to preclinical studies, but there is little evidence on its usefulness in a clinical environment.
This study was conducted by Carlos Gustavo De Moraes and his team with the objective to see if a combination of nicotinamide and pyruvate might enhance retinal ganglion cell activity in people with glaucoma, as evaluated by automated perimetry.
197 participants were evaluated for eligibility in this phase 2 randomized, double-blind, placebo-controlled clinical study at a single academic institution. 42 patients with treated open-angle glaucoma and moderate visual field loss in at least one eye were chosen and randomized from this group. The study was completed by 32 people, and 32 of them were included in the final analysis. The average age (SD) was 64.6 (9.8) years. Twenty-one (66%) of the participants were female.
To safeguard patient privacy, race and ethnicity data were acquired by self-report to ensure the distribution resembled that seen in clinical practice in the United States. Patients were recruited in April 2019 and were followed up on until December 2020. From January through May of 2021, data was examined. The dosages that were determined were as follows: Increasing nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg) oral dosages vs placebo (2:1 randomization). The main result was defined as the number of visual field test sites in the study eye improving beyond normal variability. The rates of change of visual field global indices served as secondary end goals.
The key findings of this study were as follow:
1. The study was completed by 32 individuals (32 eyes; ratio 21:11), with 22 of 29 participants (76%) assigned to the intervention group and 12 of 13 participants (92%) assigned to the placebo group.
2. The median (IQR) duration of follow-up was 2.2 (2.0-2.4) months.
3. During the trial, no significant adverse events were recorded.
4. The number of improved test sites in the therapy group was substantially greater than in the placebo group.
5. PSD rates of change indicated treatment benefit when compared to placebo, but not when compared to MD or VFI.
In conclusion, nutritional supplementation with nicotinamide and pyruvate, as proven earlier in murine glaucoma models, may improve retinal ganglion cell function in humans with glaucoma. These findings might aid in the development of novel neuroprotective treatments for glaucoma sufferers.
Reference:
De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2022;140(1):11–18. doi:10.1001/jamaophthalmol.2021.4576
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751